Developing Breakthrough Biologics, Life-changing Medicines® Corporate Update June 10, 2025 Legal Notices The information in this slide deck is current as of June 10, 2025, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements Any statements in this presentation about future expectations, plans and ...

5 June 2025 China Pharma and Biotech China Pharma & Biotech: ASCO 2025 Part 3 - positive updates from IBI363, ZL-1310, and SHR-1826; review of highlights Rebecca Liang, Ph.D. +852 2123 2656 rebecca.liang@bernsteinsg.com Haopeng Zhou +852 2123 2630 haopeng.zhou@bernsteinsg.com Extensive stage small cell lung cancer (ES-SCLC): Zai Lab provided further detail on ZL-1310 (DLL3 ADC) in 2L+ ES-SCLC at the oral session. In addition to the 68% ORR of the dose escalation group (n=28), there were notable results in t ...

LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimizationThe study is currently enrolling in dose escalationPoster to be presented June 2, 2025, 1:30 pm-4:30 pm CT BELTSVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, together ...

Core Insights - ALX Oncology is advancing ALX2004, a potential best- and first-in-class antibody-drug conjugate (ADC) targeting EGFR-expressing solid tumors, designed to maximize therapeutic efficacy while minimizing toxicity [1][2] - The U.S. FDA has cleared the IND application for ALX2004, with clinical studies set to begin in mid-2025 and initial safety data expected in the first half of 2026 [1][6] - The company plans to initiate trials for its lead therapy, evorpacept, in breast and colorectal cancers around the same time, with significant milestones anticipated in 2026 [1] ALX2004 Development Overview - ALX2004 is developed using a proprietary linker-payload platform, featuring an affinity-tuned EGFR antibody and a stable linker-Top1i payload, aimed at enhancing anti-tumor activity and reducing toxicity [3][4] - Preclinical data indicates that ALX2004 has superior stability and a favorable safety profile compared to other ADCs, showing dose-dependent activity across various tumors and EGFR expression levels [5] Clinical Trial Plans - The Phase 1 clinical trial for ALX2004 will target EGFR-expressing solid tumors, including non-small cell lung cancer and colorectal cancer, focusing on patients with relapsed or refractory cancers [6] - The trial is expected to begin in mid-2025, with initial safety data anticipated in the first half of 2026 [1][6]